RRx-001, a novel first in class epigenetic modulator, "episensitizes" colorectal patients to FOLFIRI: Preliminary resensitization data from the Phase 2 "ROCKET" study Reid, T., Carney, J., Beale, K., Clayton, C., Nguyen, H., Cho-Phan, C., Stirn, M., Ning, S., Knox, S., Oronsky, B., Scicinski, J., Caroen, S., Parker, C., Fanger, G. R., Fisher, G. AMER ASSOC CANCER RESEARCH. 2015

View details for DOI 10.1158/1538-7445.TRANSCAGEN-A1-35

View details for Web of Science ID 000370972600031